@article{10caaf5797a5478e8a66b1c9d3c94670,
title = "Phase I trial of multiple large doses of murine monoclonal antibody CO17-1A. I. Clinical aspects",
abstract = "Twenty-five patients with metastatic gastrointestinal adenocarcinoma received one to four infusions (400 mg) of murine monoclonal antibody CO17-1A. Eleven patients had mild gastrointestinal symptoms, and one had a transient flushing episode. Two of five who received three weekly infusions had readily reversible anaphylactic reactions at the time of the third infusion (day 15). There were no other toxic effects. One patient had a complete remission and is surviving at >104 weeks, and four had stable disease. The median survival for the whole group was 57 weeks. In general, the antibody infusions were well tolerated but had modest antitumor effects. [J Natl Cancer Inst 1988; 80:932-936].",
author = "Lobuglio, {Albert F.} and Saleh, {Mansoor N.} and Jeannette Lee and Khazaeli, {M. B.} and Richard Carrano and Howard Holden and Wheeler, {Richard H.}",
note = "Funding Information: 'Received March 7, 1988; revised May 10, 1988; accepted May 11, 1988. Supported by Public Health Service grant CA-45232 from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services. 'Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL. 'Veterans Administration Medical Center, Birmingham. 'Centocor, Inc., Malvern, PA. 6We thank Sharon Garrison for aid in manuscript preparation. *Correspondence to: Dr. Albert F. LoBuglio, Comprehensive Cancer Center, University of Alabama at Birmingham, 237 Tumor Institute, University Station, Birmingham, AL 35294.",
year = "1988",
month = aug,
day = "17",
doi = "10.1093/jnci/80.12.932",
language = "English",
volume = "80",
pages = "932--936",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "12",
}
